Form 8-K

8-K — Scienture Holdings, Inc.

Accession: 0001493152-26-039474

Filed: 2026-08-20

Period: 2026-08-14

CIK: 0001382574

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001382574

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 14, 2026

SCIENTURE

HOLDINGS, INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-39199

46-3673928

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

Austin Blvd.

Commack,

NY 11725

(Address

of Principal Executive Offices)

(631)

670-6039

(Registrant’s

Telephone Number)

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.00001 per share

SCNX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02

Results

of Operations and Financial Condition.

August 14, 2026, Scienture Holdings, Inc. issued a press release announcing its financial results for the quarter ending June 30, 2026,

and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K

and is incorporated herein by reference.

The

information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise

subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of

1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward

Looking Statements

This

Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal

securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are

not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange.

Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements

are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our

beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our management team’s

expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts

or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In

some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”

“potential,” “predict,” “project,” “should,” or the negative of these terms or other

similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These

statements are based on our expectations and involve risks, uncertainties and other important factors that could cause our actual results

performance or achievements (or entities in which we have an interest), or industry results, to differ materially from future results,

performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause our actual future

results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors (including

those beyond our control) could arise. Certain risks regarding our forward-looking statements are discussed in our filings with the Securities

and Exchange Commission, including an extensive discussion of these risks in our Annual Report on Form 10-K for the year ending December

31, 2025, as amended, and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking

statements which reflect management’s view only as of the date of this Current Report on Form 8-K. We undertake no obligation to

publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events, conditions or circumstances.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated August 14, 2026.

104

Cover

Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

SCIENTURE

HOLDINGS, INC.

By:

/s/

Dr. Narasimhan Mani

Dr.

Narasimhan Mani

Co-Chief

Executive Officer

Date:

August 20, 2026

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

SCIENTURE

Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base

2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced

Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating

Portfolio

COMMACK,

NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for

existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through

the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business

update and reported financial results for the three and six months ended June 30, 2026.

Second

Quarter 2026 and First Half 2026 Financial Highlights

●

Revenue

increased approximately 510% sequentially to $343,639 in Q2 2026, compared with $56,325 in Q1 2026.

●

First-half

2026 revenue increased significantly year-over-year to $399,964, compared with $10,258 for the first six months of 2025.

●

2026 gross profit was $335,779, compared to $0 in Q2 2025, with Q2 2026 gross margin being approximately 97.7%.

●

First-half

2026 gross profit increased to $389,629, compared with $673 for the first six months of 2025, with a gross margin of approximately

97.4% for the first half of 2026.

●

2026 operating expenses decreased approximately 41% year-over-year to approximately $3.0 million, compared with approximately $5.2

million in Q2 2025, demonstrating continued expense management and operating discipline.

●

First-half

2026 operating expenses decreased approximately 24% to about $6.6 million, compared with approximately $8.7 million during the first

six months of 2025.

●

2026 operating loss improved approximately 48% to about $2.7 million, compared with an operating loss of approximately $5.2 million

in Q2 2025.

●

2026 net loss narrowed approximately 58% to about $2.8 million, compared with a net loss of approximately $6.7 million in Q2 2025.

Basic and diluted net loss per share improved to $0.07 from $0.48 during that time.

●

First-half

2026 net loss narrowed approximately 36% to about $6.2 million, compared with approximately $9.8 million for the first six months

of 2025. Basic and diluted net loss per share improved to $0.16 from $0.83 during that time.

●

of June 30, 2026, the Company had cash, cash equivalents and restricted cash of approximately $11.2 million compared to approximately

$6.7 million of cash and cash equivalents as of December 31, 2025.

Key

Operational Highlights in Q2 2026 and Subsequent Events:

●

United

States Patent and Trademark Office (USPTO) granted a second patent covering REZENOPY™ (naloxone hydrochloride) Nasal

Spray 10 mg, strengthening intellectual property protection for the product through 2041.

●

United

States Patent and Trademark Office (USPTO) granted a third patent covering Arbli™ (losartan potassium) oral suspension,

further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041.

●

Secured

formulary coverage for REZENOPY™ with a large national health plan and expanded the commercial team to support market

penetration and growth.

●

Expanded

ARBLI™ payer coverage and commercial access, adding approximately 12.5 million covered lives.

●

Commenced

the commercial launch of REZENOPY™ and began fulfillment of initial purchase orders, marking an important milestone

in the Company’s commercialization strategy.

Narasimhan

Mani, President, Interim CFO, and Co-CEO of Scienture, commented, “We believe our second-quarter results demonstrate that Scienture

has reached an important inflection point. Revenue for Q2 20226 increased about 510% sequentially, from approximately $56,000 in the

first quarter to approximately $344,000 in the second quarter. At the same time, we generated gross margins of approximately 98%, reduced

operating expenses by about 41% year-over-year and narrowed our net loss by approximately 58%. We also ended the quarter with approximately

$11.2 million in cash, cash equivalents and restricted cash, compared with about $6.7 million at year-end 2025, providing us with a stronger

financial position as we execute the next phase of our commercial growth strategy. We believe these results demonstrate that we are on

the right path to deliver value added business growth in the coming quarters and that we are beginning to realize the operating leverage

we have been working toward.”

“Arbli’s

continued commercial progress gives us confidence in our ability to build and scale differentiated pharmaceutical products, and we believe

we have only begun to realize its market opportunity,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We

are expanding payer access and commercial availability for Arbli™ while simultaneously bringing REZENOPY™

online commercially in the third quarter of 2026. With Arbli™ continuing to gain traction and REZENOPY™

becoming our second commercial-stage product, we believe Scienture is positioned to meaningfully accelerate top-line revenue growth during

the second half of 2026 and into 2027. With two differentiated FDA-approved products, approximately 98% gross margins, a strengthened

cash position and a more disciplined operating expense structure, we believe we have turned an important corner and established a clear

path toward our goal of achieving profitability in 2027.”

About

Arbli™

is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first

and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf

life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than

six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic

nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™

provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™

provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded

losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™

is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle

as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the

date of manufacture when stored at room temperature.

INDICATION

Arbli™

is an angiotensin II receptor blocker (ARB) indicated for:

●

Treatment

of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk

of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

●

Reduction

of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

●

Treatment

of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT

SAFETY INFORMATION

●

not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible.

Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™

can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second

and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.

●

not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™

in patients with renal impairment (GFR <60 mL/min).

●

not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in

patients with severe hepatic impairment.

●

The

most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion,

and back pain.

You

are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also contact Scienture at 1-833-754-4917.

Please

see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About

Hypertension

(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According

to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million

people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.

Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk

of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and

drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic

blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10mg, is indicated for the emergency treatment of known or suspected opioid overdose, as manifested

by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY™ nasal spray is not

a substitute for emergency medical care. If the desired response is not obtained after 2 to 3 minutes, administer a second dose of REZENOPY™

nasal spray using a new REZENOPY™ nasal spray device. If there is still no response and additional doses are available,

administer additional doses of REZENOPY™ every 2 to 3 minutes, alternating nostrils and using a new REZENOPY™,

until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency

medical assistance

REZENOPY™

nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT

SAFETY INFORMATION

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid

overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate

administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Important

Safety Information

●

Contraindications:

REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to

any of the other ingredients.

●

Warnings

and Precautions:

●

Risk

of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under

continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.

●

Risk

of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists

or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

●

Precipitation

of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal

may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.

●

Risk

of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These

events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar

adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

●

Adverse

Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal

pain, nasopharyngitis, and dysgeusia.

For

complete product information, including Patient Information, please refer to the full Prescribing Information.

About

Scienture Holdings, Inc.

SCIENTURE

HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company

focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market

needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals

who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare

systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and

channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary

Statements Regarding Forward-Looking Statements

This

press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities

laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking

statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,

our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management

team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the

success those products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies related to those products.

In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including

any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following

words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”

“intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,”

“should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that

a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are

beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking

statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating

to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential

dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our

ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual

property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us;

unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on

Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking

statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided

by law.

Contact:

SCIENTURE

HOLDINGS, INC.

Austin Blvd

Commack,

NY 11725

Email:

IR@Scienture.com

Scienture

Holdings, Inc. formerly TRxADE HEALTH, INC.

Condensed

Consolidated Balance Sheets

of June 30, 2026 and December 31, 2025

(Unaudited)

June 30, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$ 8,188,140

$ 6,662,008

Accounts receivable, net

385,313

731,328

Inventory

203,074

213,408

Prepaid expenses

425,370

262,278

Deferred offering costs

47,384

Total current assets

9,201,897

7,916,406

Restricted cash

3,012,271

Property, plant and equipment, net

14,500

15,500

Notes receivable

5,000,000

Interest receivable

437,500

250,000

Intangible assets, net

70,065,371

70,973,064

Operating lease right-of-use assets

2,468

23,360

Total assets

$ 87,734,007

$ 84,178,330

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$ 916,771

$ 1,443,266

Accrued liabilities

503,634

657,034

Operating lease liability - current

2,546

24,137

Warrant liability

10,914

Note payable, net of debt discount - current portion

1,118,349

Development agreement liability - current portion

485,000

600,000

Total current liabilities

3,026,300

2,735,351

Note payable, net of debt discount

9,568,586

Development agreement liability

285,000

Deferred tax liability

11,037,595

Total liabilities

23,632,481

14,057,946

Commitments and contingencies (Note 13)

Stockholders’ equity:

Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025

Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both June 30, 2026 and December 31, 2025

Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025

Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025

Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively

410

406

Additional paid-in capital

150,876,988

150,671,215

Accumulated deficit

(86,775,872 )

(80,551,237 )

Total stockholders’ equity

64,101,526

70,120,384

Total liabilities and stockholders’ equity

$ 87,734,007

$ 84,178,330

Scienture

Holdings, Inc. formerly TRxADE HEALTH, INC.

Condensed Consolidated Statements Of Operations

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenues

$ 343,639

$ -

$ 399,964

$ 10,258

Cost of sales

7,860

10,335

9,585

Gross profit

335,779

389,629

673

Operating expenses:

Wage and salary expense

411,411

773,739

831,419

1,469,807

Professional fees

963,752

209,763

1,896,304

622,613

Accounting and legal expense

117,815

381,683

443,993

852,508

Technology expense

7,139

21,408

22,902

83,028

General and administrative

368,790

2,927,764

1,443,654

4,283,712

Research and development

1,166,605

843,549

1,960,589

1,418,228

Total operating expenses

3,035,512

5,157,906

6,598,861

8,729,896

Operating loss

(2,699,733 )

(5,157,906 )

(6,209,232 )

(8,729,223 )

Non-operating income (expense):

Change in fair value of warrant liability

76,122

10,910

722,108

Change in fair value of derivative liability

(662,916 )

(59,594 )

Loss on conversion of note payable

(96,646 )

Loss on disposition of subsidiaries

(385,528 )

Interest income

147,147

63,148

280,491

88,590

Interest expense

(269,785 )

(653,493 )

(306,804 )

(1,324,277 )

Total non-operating expense

(122,638 )

(1,562,667 )

(15,403 )

(1,055,347 )

Benefit (provision) for income taxes

Net loss

$ (2,822,371 )

$ (6,720,573 )

$ (6,224,635 )

$ (9,784,570 )

Net loss per common share

Basic

$ (0.07 )

$ (0.48 )

$ (0.16 )

$ (0.83 )

Diluted

$ (0.07 )

$ (0.48 )

$ (0.16 )

$ (0.83 )

Weighted average common shares outstanding

Basic

39,615,815

14,141,443

39,615,815

11,844,024

Diluted

39,615,815

14,141,443

39,615,815

11,844,024

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4127 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Entity File Number

001-39199

Entity Registrant Name

SCIENTURE

HOLDINGS, INC.

Entity Central Index Key

0001382574

Entity Tax Identification Number

46-3673928

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Austin Blvd.

Entity Address, City or Town

Commack

Entity Address, State or Province

Entity Address, Postal Zip Code

11725

City Area Code

(631)

Local Phone Number

670-6039

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.00001 per share

Trading Symbol

SCNX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration